We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Nordion Reports Strategic Realignment of the Company

By MedImaging International staff writers
Posted on 24 Sep 2012
Print article
Nordion, Inc. (Ottawa, Ontario, Canada), a global health science company, announced a strategic realignment of the business designed to focus on improving the execution of Nordion’s business strategy.

The plan includes transitioning Nordion to a business unit model with two distinct business units: targeted therapies and specialty isotopes, each of which will be supported by centralized corporate functions. The specialty isotopes business will include two segments: sterilization technologies and medical isotopes.

The company also announced the appointment of Jeff Brown, chief executive officer and founding member of Brown Equity Partners, LLC (Corona Del Mar, CA, USA), to its board of directors.

“The strategic realignment is designed to take into account the unique product life cycles and the needs of our customers in each of our businesses,” said Steve West, chief executive officer, Nordion. “The new organizational model is intended to allow for quicker decision making and provide the Nordion team with improved agility, clearer focus, and direct leadership accountability to better serve our customers and build shareholder value.”

The new Nordion leadership team intends to focus on appropriately allocating talent and resources to better support the unique characteristics of each business and their respective portfolios. Moreover, they plan to continue to evaluate opportunities that are expected to better serve our customers.

These announcements align with Nordion’s strategic priorities. The targeted therapies business unit is expected to continue to focus on building an interventional oncology business. The specialty isotopes business plans to concentrate on maintaining sterilization technologies’ cash generation, making selective growth investments and optimizing the medical isotope business.

Nordion plans to begin operating in the new business unit model on November 1, 2012, for the start of the company’s 2013 fiscal year. Nordion expects to continue to report financial results by its three business segments targeted therapies, sterilization technologies, and medical isotopes. Targeted Therapies will focus on TheraSphere while contract manufacturing is expected to be repositioned and reported under medical isotopes. The company’s segment reporting will incorporate the changes in the portfolios managed under each segment and comparative historic segment financial information is expected to be restated to align with these changes.

Nordion is a global health science company that provides products used for the prevention, diagnosis, and treatment of disease. The company is a leading provider of medical isotopes, targeted therapies, and sterilization technologies.

Related Links:

Nordion



New
Gold Member
X-Ray QA Meter
T3 AD Pro
Ultrasound Color LCD
U156W
New
3T MRI Scanner
MAGNETOM Cima.X
New
Imaging Table
CFPM201

Print article
Radcal

Channels

Radiography

view channel
Image: The new X-ray detector produces a high-quality radiograph (Photo courtesy of ACS Central Science 2024, DOI: https://doi.org/10.1021/acscentsci.4c01296)

Highly Sensitive, Foldable Detector to Make X-Rays Safer

X-rays are widely used in diagnostic testing and industrial monitoring, from dental checkups to airport luggage scans. However, these high-energy rays emit ionizing radiation, which can pose risks after... Read more

MRI

view channel
Image: Artificial intelligence models can be trained to distinguish brain tumors from healthy tissue (Photo courtesy of 123RF)

AI Can Distinguish Brain Tumors from Healthy Tissue

Researchers have made significant advancements in artificial intelligence (AI) for medical applications. AI holds particular promise in radiology, where delays in processing medical images can often postpone... Read more

Nuclear Medicine

view channel
Image: Example of AI analysis of PET/CT images (Photo courtesy of Academic Radiology; DOI: 10.1016/j.acra.2024.08.043)

AI Analysis of PET/CT Images Predicts Side Effects of Immunotherapy in Lung Cancer

Immunotherapy has significantly advanced the treatment of primary lung cancer, but it can sometimes lead to a severe side effect known as interstitial lung disease. This condition is characterized by lung... Read more

General/Advanced Imaging

view channel
Image: Cleerly offers an AI-enabled CCTA solution for personalized, precise and measurable assessment of plaque, stenosis and ischemia (Photo courtesy of Cleerly)

AI-Enabled Plaque Assessments Help Cardiologists Identify High-Risk CAD Patients

Groundbreaking research has shown that a non-invasive, artificial intelligence (AI)-based analysis of cardiac computed tomography (CT) can predict severe heart-related events in patients exhibiting symptoms... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.